Sharekhan

Wanbury Ltd

Wed 21/05/2025,15:57:24 NSE: WANBURY

₹ 291.81 1.93 (0.67%)
BUY NOW Buy Wanbury Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Wanbury Ltd

Wed 21/05/2025,16:1:0

Wanbury Ltd

Wed 21/05/2025,15:57:24 | NSE : WANBURY

₹ 291.811.93 (0.67%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 280.00

Previous Close

₹ 289.88

Volume

40434

Mkt Cap ( Rs. Cr)

₹956.28

High

₹ 298.00

Low

₹ 278.55

52 Week High

₹ 329.70

52 Week Low

₹ 131.20

Book Value Per Share

₹ 11.83

Dividend Yield

0.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Wanbury Ltd

Your Vote -

Buy

50.00%

Hold

16.67%

Sell

33.33%

50.00%

6 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

NaN%

Sell Order Quantity

NaN%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Wanbury Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Wanbury’s Patalganga facility secures GMP certification from ANVISA

    20 May 2025, 11:00AM Wanbury has announced that its active pharmaceutical ingredient (API) manufacturing facility in Patalganga has received the Certificate of Good Manufa

  • Wanbury - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    20 May 2025, 9:00AM Grant of Good Manufacturing Practices Certificate (CBPF) by ANVISA, Brazil FDA for its Patalganga facility, Maharashtra.

  • Wanbury - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    15 May 2025, 10:21PM WANBURY LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

  • Wanbury - Announcement under Regulation 30 (LODR)-Change in Management

    15 May 2025, 10:15PM Intimation of Appointment of Secretarial Auditor, Cost Auditor, Internal Auditor and Tax Auditor

  • Wanbury - Change in Management

    15 May 2025, 10:12PM Wanbury Limited has informed the Exchange about change in Management

  • Wanbury - Integrated Filing (Financial)

    15 May 2025, 10:00PM Standalone & Consolidated Audited Financial Results of the Company for the fourth quarter and year ended on 31st March, 2025.

  • Wanbury - Outcome of Board Meeting

    15 May 2025, 9:40PM Wanbury Limited has informed the Exchange regarding Outcome of Board Meeting held on May 15, 2025.

  • Wanbury Q4 net profit zooms 150.74% at Rs 20.26 cr

    15 May 2025, 9:30PM The company reported standalone net profit of Rs 20.26 crore for the quarter ended March 31, 2025 as compared to Rs 8.08 crore in the same period last

  • Wanbury - Board Meeting Outcome for Outcome Of Board Meeting 15 May 2025

    15 May 2025, 9:30PM As per Regulation 33 of SEBI (LODR), Regulations, 2015, we are enclosing herewith the following:\r\na) Standalone & Consolidated Audited Financial Res

  • Wanbury - Outcome of Board Meeting

    15 May 2025, 9:21PM Wanbury Limited has informed the Exchange regarding Board meeting held on May 15, 2025.

  • Wanbury - Press Release

    12 May 2025, 2:29PM Wanbury Limited has informed the Exchange regarding a press release dated May 12, 2025, titled ""Grant of Good Manufacturing Practices Certificate (CB

  • Wanbury - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    12 May 2025, 2:16PM Press Release - Grant of Good Manufacturing Practices Certificate (CBPF) by ANVISH for its Tanuku facility, Andhra Pradesh.

  • Wanbury - Board Meeting Intimation

    8 May 2025, 5:19PM WANBURY LIMITED has informed the Exchange about Board Meeting to be held on 15-May-2025 to inter-alia consider and approve the Audited Financial resul

  • Wanbury - Board Meeting Intimation for Notice Of Board Meeting For Approving The Audited Financial Results & Statements Of Th

    8 May 2025, 5:07PM Wanbury Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2025 ,inter alia, to consider and approve

  • Wanbury - Press Release

    23 Apr 2025, 10:25AM Wanbury Limited has informed the Exchange regarding a press release dated April 23, 2025, titled ""Intimation to implement the SAP S/4 HANA Private Cl

  • Wanbury embarks on digital transformation with SAP S/4HANA private cloud implementation

    23 Apr 2025, 10:54AM Wanbury Ltd has announced a strategic move to adopt the SAP S/4HANA Private Cloud platform as part of its broader digital transformation initiative. I

  • Wanbury - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    23 Apr 2025, 10:28AM Intimation to implement SAP S/4 HANA Private Cloud Platform

  • Wanbury - Disclosure under SEBI Takeover Regulations

    19 Apr 2025, 11:24PM Expert Chemicals (India) Pvt. Ltd. has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of I

  • Wanbury has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    18 Apr 2025, 8:31PM As of March 2025, 39.76% is owned by Promoters and 60.24% by Public. <p align=justify> Among Promoters holding, Indian Promoters holds 30.53% and Fore

  • Wanbury - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    11 Apr 2025, 5:47PM Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations,2018 of Wanbury Limited

  • Wanbury - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    11 Apr 2025, 5:43PM Wanbury Limited has informed the Exchange about Certificate under Reg 74(5) of SEBI (Depositories and Participants) Regulations, 2018

  • Wanbury - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

    7 Apr 2025, 3:47PM <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border='1px'><tr> <td><b>Sr. No.</b></td

  • Wanbury - Press Release

    3 Apr 2025, 9:43AM Wanbury Limited has informed the Exchange regarding a press release dated April 03, 2025, titled ""Intimation of improved capacity utilization for Q4

  • Wanbury - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    3 Apr 2025, 9:48AM Intimation of Improved capacity utilization for Q4 and improved margins

  • Wanbury - Press Release

    2 Apr 2025, 5:05PM Wanbury Limited has informed the Exchange regarding a press release dated April 02, 2025, titled ""Intimation of schedule of Investors/ Analysts Plant

  • Wanbury - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    2 Apr 2025, 5:09PM Intimation of schedule of Investors/ Analysts Plant Visit

  • Wanbury - Trading Window-XBRL

    27 Mar 2025, 3:08PM WANBURY LIMITED has informed the Exchange about Closure of Trading Window

  • Wanbury - Trading Window

    27 Mar 2025, 3:05PM Wanbury Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

  • Wanbury - Press Release

    24 Mar 2025, 12:31PM Wanbury Limited has informed the Exchange regarding a press release dated March 24, 2025, titled ""Press Release - Wanbury Limited"".

  • Wanbury Limited launches two new products: C-RED Iron Tablets and Ketamine Hydrochloride API

    24 Mar 2025, 1:00PM Mumbai, India &ndash; Wanbury Limited, a leading pharmaceutical company with a significant presence in the global API market and domestic branded form

  • Wanbury - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    24 Mar 2025, 12:39PM Wanbury Limited (\Wanbury\), a pharmaceutical company with a presence in the global API market and domestic branded formulations, please to inform tha

  • Wanbury - Press Release

    6 Mar 2025, 8:47AM Wanbury Limited has informed the Exchange regarding a press release dated March 06, 2025, titled ""Disclosure under Regulation 30 of SEBI (Listing Obl

  • Wanbury Ltd achieves significant interest cost savings through debt refinancing

    6 Mar 2025, 9:32AM Wanbury Limited ("Wanbury"), a pharmaceutical company with a strong presence in the global API market and domestic branded formulations, has reached a

  • Wanbury - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    6 Mar 2025, 8:52AM Disclosure under regulation 30 of SEBI (LODR) Regulations, 2015 Press Release on Refinancing of Outstanding Debentures

  • Wanbury - Announcement under Regulation 30 (LODR)-Allotment

    28 Feb 2025, 5:29PM This is to inform that the Day to Day Affairs Committee (Constituted by the Board of Directors of Wanbury Limited) in its meeting held today have appr

  • Wanbury - Allotment of Securities

    28 Feb 2025, 5:27PM Wanbury Limited has informed the Exchange regarding allotment of 1750 securities pursuant to Preferential Issue at its meeting held on February 28, 20

  • Wanbury's Patalganga mfg facility receives CBPF (GMP) Certificate

    20 May 2025 , 10:34AM Wanbury's Patalganga mfg facility receives CBPF (GMP) Certificate from The Office of ANVISA (Brazil FDA)
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Wanbury Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 232.5001 137.8934 56.8788 69.2111 -42.2402
Liabilities 232.5001 137.8934 56.8788 69.2111 -42.2402
Equity 32.7705 32.7455 32.7055 32.6655 25.0151
Gross Profit 76.3192 70.0022 23.1719 35.3128 18.0192
Net Profit 30.5301 30.3995 -10.3958 81.4739 -12.6057
Cash From Operating Activities 26.1016 4.017 19.7972 40.5231 16.6815
NPM(%) 5.09 5.28 -2.08 15.93 -3.21
Revenue 599.5142 575.6498 499.6469 511.1857 392.5175
Expenses 523.195 505.6476 476.475 475.8729 374.4983
ROE(%) 78.77 78.43 -26.82 210.22 -32.52

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
29 Jul 2010 1 10 0 78.6
12 Mar 2009 0.5 5 0 45.5
13 Sep 2007 2 20 0 115

Peers

Other companies within the same industry or sector that are comparable to Wanbury Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 810.15 -0.84 26.88 165.65 301.39 0.62
Lotus Eye Hospital and Institute Ltd 74.06 0.78 308.58 603.61 14.01 0.68
Vaishali Pharma Ltd 12.85 -1.15 428.33 311.13 2.76 0.00
Astec Lifesciences Ltd 701.25 -1.59 0.00 569.15 -687.11 0.00

Company Info

The Company was incorporated on 11th August 1988, as a Private Limited Company under the name of `Pearl Distributors Private Limited'. The name of the Company was changed to "Pearl Organics Private Limited" on 17th January, 1991. The Company was converted into a Public Limited Company on 6th August, 1991. The main object of the Company is to undertake the manufacture and sale of pharmaceuticals, medicines, drugs and organic chemicals. A substantial portion of the production of these products are intended for exports. The Company has set up a full-fledged export marketing division consisting of experienced professionals. The Company has already secured orders worth Rs 1.07 crores from West European Countries. The Company is in the process of negotiating further orders with foreign buyers for export of its products. The main objects of the Company are fully set out in Memorandum of Association of the Company. The Company has no subsidiary. The Company has been principally promoted by Mr.K. Chandran along with his associates Mr K Chandran has a rich experience of over 12 years in marketing of pharmaceutical formulation in local & international markets. During his 12 years tenure he has worked in various capacities including as business manager in one of the largest pharmaceutical company. He was also head of export division of an export oriented pharmaceutial Company. 2004 - Pearl Organics to establish new R&D centre in Mumbai 2006 - Wanbury acquires generic company in Spain 2007 - Wanbury Ltd has recommended dividend of Rs 2 per equity share i.e. @ 20% 2008 - Wanbury Ltd has recommended dividend of Rs 0.50 per equity shares i.e. @5% 2010 - Wanbury Ltd has recommended a dividend of Rs. 1/- per equity share 2016 - Wanbury Won Pharma IT Innovation Award 2016 - Wanbury bags 2 awards at recently held AWACS awards 2024 -Wanbury Limited received a Certificate of Suitability (CEP) forthe launch of its new product, Dextromethorphan (API). -Wanbury Limited wins two Safety Awards for its API Manufacturing site in Patalganga for the third consecutive year at the Maharashtra Safety Awards Competition 2023, conducted by Maharashtra State Government.

The Company was incorporated on 11th August 1988, as a Private Limited Company under the name of `Pearl Distributors Private Limited'. The name of the Company was changed to "Pearl Organics Private Limited" on 17th January, 1991. The Company was converted into a Public Limited Company on 6th August, 1991. The main object of the Company is to undertake the manufacture and sale of pharmaceuticals, medicines, drugs and organic chemicals. A substantial portion of the production of these products are intended for exports. The Company has set up a full-fledged export marketing division consisting of experienced professionals. The Company has already secured orders worth Rs 1.07 crores from West European Countries. The Company is in the process of negotiating further orders with foreign buyers for export of its products. The main objects of the Company are fully set out in Memorandum of Association of the Company. The Company has no subsidiary. The Company has been principally promoted by Mr.K. Chandran along with his associates Mr K Chandran has a rich experience of over 12 years in marketing of pharmaceutical formulation in local & international markets. During his 12 years tenure he has worked in various capacities including as business manager in one of the largest pharmaceutical company. He was also head of export division of an export oriented pharmaceutial Company. 2004 - Pearl Organics to establish new R&D centre in Mumbai 2006 - Wanbury acquires generic company in Spain 2007 - Wanbury Ltd has recommended dividend of Rs 2 per equity share i.e. @ 20% 2008 - Wanbury Ltd has recommended dividend of Rs 0.50 per equity shares i.e. @5% 2010 - Wanbury Ltd has recommended a dividend of Rs. 1/- per equity share 2016 - Wanbury Won Pharma IT Innovation Award 2016 - Wanbury bags 2 awards at recently held AWACS awards 2024 -Wanbury Limited received a Certificate of Suitability (CEP) forthe launch of its new product, Dextromethorphan (API). -Wanbury Limited wins two Safety Awards for its API Manufacturing site in Patalganga for the third consecutive year at the Maharashtra Safety Awards Competition 2023, conducted by Maharashtra State Government.

Read More

Parent Organisation

Wanbury Ltd.

Founded

11/08/1988

Managing Director

NSE Symbol

WANBURYEQ

FAQ

The current price of Wanbury Ltd is ₹ 291.81.

The 52-week high for Wanbury Ltd is ₹ 298.00 and the 52-week low is ₹ 278.55.

The market capitalization of Wanbury Ltd is currently ₹ 956.28. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Wanbury Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Wanbury Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Wanbury Ltd shares.

The CEO of Wanbury Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT